JP2018537975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537975A5 JP2018537975A5 JP2018527739A JP2018527739A JP2018537975A5 JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5 JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260854P | 2015-11-30 | 2015-11-30 | |
| US62/260,854 | 2015-11-30 | ||
| US201662289744P | 2016-02-01 | 2016-02-01 | |
| US201662289727P | 2016-02-01 | 2016-02-01 | |
| US62/289,744 | 2016-02-01 | ||
| US62/289,727 | 2016-02-01 | ||
| US201662409105P | 2016-10-17 | 2016-10-17 | |
| US62/409,105 | 2016-10-17 | ||
| PCT/IB2016/057017 WO2017093844A1 (en) | 2015-11-30 | 2016-11-22 | Site specific her2 antibody drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537975A JP2018537975A (ja) | 2018-12-27 |
| JP2018537975A5 true JP2018537975A5 (enExample) | 2020-01-16 |
| JP6979950B2 JP6979950B2 (ja) | 2021-12-15 |
Family
ID=57485830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527739A Expired - Fee Related JP6979950B2 (ja) | 2015-11-30 | 2016-11-22 | 部位特異的ｈｅｒ２抗体薬物コンジュゲート |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10689458B2 (enExample) |
| EP (1) | EP3383918A1 (enExample) |
| JP (1) | JP6979950B2 (enExample) |
| KR (2) | KR102312149B1 (enExample) |
| CN (1) | CN108473591B (enExample) |
| AU (1) | AU2016363373A1 (enExample) |
| BR (1) | BR112018010102A2 (enExample) |
| CA (1) | CA2949032A1 (enExample) |
| CO (1) | CO2018005433A2 (enExample) |
| IL (1) | IL259651B2 (enExample) |
| MX (1) | MX2018006582A (enExample) |
| PH (1) | PH12018501043A1 (enExample) |
| RU (1) | RU2745565C2 (enExample) |
| SG (2) | SG10202005102YA (enExample) |
| TW (3) | TWI726942B (enExample) |
| WO (1) | WO2017093844A1 (enExample) |
| ZA (1) | ZA201803205B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| HUE070615T2 (hu) * | 2016-10-17 | 2025-06-28 | Pfizer | Anti-EDB antitestek és antitest-gyógyszer konjugátumok |
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| WO2019232449A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Splicing modulator antibody-drug conjugates and methods of use |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| WO2021086981A1 (en) * | 2019-10-29 | 2021-05-06 | Cspc Dophen Corporation | Compositions and methods for treating cancer using anti-her2 antibody drug conjugate |
| KR20220119445A (ko) | 2019-12-20 | 2022-08-29 | 화이자 인코포레이티드 | 부위 특이적 her2 항체-약물 접합체를 사용한 치료 |
| CN115052632B (zh) * | 2020-01-15 | 2025-01-14 | 北京海步医药科技有限公司 | 靶向多肽-药物缀合物及其用途 |
| CA3190798A1 (en) | 2020-08-04 | 2022-02-10 | Pfizer Inc. | Treatment with site specific her2 antibody-drug conjugates |
| CN112202628B (zh) * | 2020-09-08 | 2022-09-02 | 杭州涂鸦信息技术有限公司 | 一种WiFi模块串口协议自动化测试系统及方法 |
| CN112285361B (zh) * | 2020-09-27 | 2023-12-05 | 中国人民解放军空军军医大学 | 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂 |
| PE20231512A1 (es) | 2020-10-25 | 2023-09-26 | Araris Biotech Ag | Medios y metodos para producir conjugados de ligador-anticuerpo |
| CA3206798A1 (en) * | 2021-02-18 | 2022-08-25 | Jianmin Fang | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer |
| AU2022358772A1 (en) * | 2021-10-10 | 2024-05-02 | Elixiron Immunotherapeutics (hong Kong) Limited | Method of treating diseases with anti-pd-l1/il-10 fusion proteins |
| WO2023072934A1 (en) * | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
| CN118804932A (zh) * | 2022-01-26 | 2024-10-18 | 百奥赛图(北京)医药科技股份有限公司 | 抗her2/trop2抗体及其用途 |
| WO2024162772A1 (ko) * | 2023-02-01 | 2024-08-08 | 주식회사 에이티지씨 | 생체 내 지속성이 증가된 생리활성물질의 결합체 |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
| CN120738196B (zh) * | 2025-09-03 | 2025-12-16 | 浙江博锐生物制药有限公司 | 编码抗her2抗体的核酸分子及其应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9116610D0 (en) | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US20080152660A1 (en) | 2005-03-03 | 2008-06-26 | Bradshaw Curt W | Anti-Angiogenic Compounds |
| EP1940470B1 (en) | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| WO2008032833A1 (en) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| US20090098115A1 (en) * | 2006-10-20 | 2009-04-16 | Lisa Michele Crocker | Cell lines and animal models of HER2 expressing tumors |
| CA2698541C (en) | 2007-10-19 | 2018-01-09 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| BRPI0907046A2 (pt) | 2008-01-18 | 2015-07-28 | Medimmune Llc | Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo |
| ES2643239T3 (es) | 2008-01-31 | 2017-11-21 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| WO2011005481A1 (en) | 2009-06-22 | 2011-01-13 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
| MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CA2818635C (en) | 2010-12-06 | 2021-06-15 | National Reseach Council Of Canada | Antibodies selective for cells presenting erbb2 at high density |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| AR088693A1 (es) | 2011-11-11 | 2014-06-25 | Rinat Neuroscience Corp | Anticuerpos especificos para trop-2 y sus usos |
| CN104185477B (zh) * | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| WO2013165690A1 (en) | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| HK1207388A1 (en) | 2012-05-15 | 2016-01-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2014022592A1 (en) | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| US9850313B2 (en) | 2012-08-03 | 2017-12-26 | Board Of Regents Of The University Of Nebraska | Cancer biomarkers and methods of use thereof |
| HRP20190366T1 (hr) | 2012-10-12 | 2019-04-19 | Medimmune Limited | Pirolobenzodiazepini i njihovi konjugati |
| HRP20171264T1 (hr) | 2012-10-12 | 2017-10-20 | Adc Therapeutics Sa | Konjugati protutijela anti-her2-pirolobenzodiazepina |
| KR101763499B1 (ko) | 2012-11-07 | 2017-07-31 | 화이자 인코포레이티드 | 항-il-13 수용체 알파 2 항체 및 항체-약물 접합체 |
| BR112015018899B1 (pt) | 2013-02-08 | 2023-09-26 | Novartis Ag | Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira |
| JP6445519B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| WO2015002486A1 (ko) | 2013-07-03 | 2015-01-08 | 서울대학교산학협력단 | 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합 |
| US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| US9239324B2 (en) | 2013-12-06 | 2016-01-19 | Gang Chen | Antibody-binding protein-drug conjugate and methods of use |
| CN106163568B (zh) | 2013-12-23 | 2021-03-23 | 拜耳制药股份公司 | 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc） |
| KR101871088B1 (ko) | 2014-01-27 | 2018-06-25 | 화이자 인코포레이티드 | 이관능성 세포독성제 |
| HRP20250041T1 (hr) * | 2014-02-28 | 2025-03-14 | Merus N.V. | Antitijelo koje veže erbb-2 i erbb-3 |
| ES2819863T3 (es) | 2014-04-11 | 2021-04-19 | Medimmune Llc | Anticuerpos contra HER2 biespecíficos |
| AU2015271100B2 (en) * | 2014-06-06 | 2020-07-30 | Redwood Bioscience, Inc. | Anti-HER2 antibody-maytansine conjugates and methods of use thereof |
| BR112017018706B1 (pt) | 2015-03-20 | 2023-01-24 | Pfizer Inc | Agentes citotóxicos bifuncionais contendo o farmacoforo cti, composição farmacêutica e uso dos mesmos |
| TWI703160B (zh) | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
-
2016
- 2016-11-21 TW TW105138129A patent/TWI726942B/zh not_active IP Right Cessation
- 2016-11-21 TW TW108126399A patent/TWI727380B/zh not_active IP Right Cessation
- 2016-11-21 US US15/356,750 patent/US10689458B2/en active Active
- 2016-11-21 CA CA2949032A patent/CA2949032A1/en not_active Abandoned
- 2016-11-21 TW TW110100847A patent/TWI778491B/zh not_active IP Right Cessation
- 2016-11-22 JP JP2018527739A patent/JP6979950B2/ja not_active Expired - Fee Related
- 2016-11-22 MX MX2018006582A patent/MX2018006582A/es unknown
- 2016-11-22 KR KR1020207030005A patent/KR102312149B1/ko not_active Expired - Fee Related
- 2016-11-22 WO PCT/IB2016/057017 patent/WO2017093844A1/en not_active Ceased
- 2016-11-22 SG SG10202005102YA patent/SG10202005102YA/en unknown
- 2016-11-22 KR KR1020187018244A patent/KR102208317B1/ko not_active Expired - Fee Related
- 2016-11-22 BR BR112018010102-8A patent/BR112018010102A2/pt not_active IP Right Cessation
- 2016-11-22 EP EP16806285.9A patent/EP3383918A1/en not_active Withdrawn
- 2016-11-22 SG SG11201803676PA patent/SG11201803676PA/en unknown
- 2016-11-22 CN CN201680072749.4A patent/CN108473591B/zh not_active Expired - Fee Related
- 2016-11-22 RU RU2018119683A patent/RU2745565C2/ru active
- 2016-11-22 AU AU2016363373A patent/AU2016363373A1/en not_active Abandoned
-
2018
- 2018-05-15 ZA ZA2018/03205A patent/ZA201803205B/en unknown
- 2018-05-16 PH PH12018501043A patent/PH12018501043A1/en unknown
- 2018-05-24 CO CONC2018/0005433A patent/CO2018005433A2/es unknown
- 2018-05-28 IL IL259651A patent/IL259651B2/en unknown
-
2020
- 2020-06-03 US US16/891,460 patent/US20200377615A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537975A5 (enExample) | ||
| RU2018119683A (ru) | Сайт-специфические конъюгаты антитела к her2 и лекарственного средства | |
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| TWI906070B (zh) | 抗體-藥物結合物之用途 | |
| AU2015205588B2 (en) | Duocarmycin ADCs for use in treatment of endometrial cancer | |
| JP2015534577A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| FI3283521T3 (fi) | Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan | |
| JP2017514905A5 (enExample) | ||
| ME02919B (me) | Konjugati humanog antitijela sa lijekom protiv tkivnog faktora | |
| JP2016505513A5 (enExample) | ||
| JP2012522512A5 (enExample) | ||
| JP2016528251A5 (enExample) | ||
| CN118973617A (zh) | 缀合物、组合物及使用方法 | |
| CN106999606A (zh) | 抗体药物偶联物 | |
| JP2016540826A5 (enExample) | ||
| JP2020507569A5 (enExample) | ||
| TW202525806A (zh) | 基於分子膠降解劑之抗體-藥物結合物及其用途 | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| BR122024023391A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor |